Risk factors for acute GVHD and survival after hematopoietic cell transplantation

Madan Jagasia, Mukta Arora, Mary E D Flowers, Nelson J. Chao, Philip L. McCarthy, Corey S. Cutler, Alvaro Urbano-Ispizua, Steven Z. Pavletic, Michael D. Haagenson, Mei Jie Zhang, Joseph H. Antin, Brian J. Bolwell, Christopher Bredeson, Jean Yves Cahn, Mitchell Cairo, Robert Peter Gale, Vikas Gupta, Stephanie J. Lee, Mark R Litzow, Daniel J. WeisdorfMary M. Horowitz, Theresa Hahn

Research output: Contribution to journalArticle

263 Citations (Scopus)

Abstract

Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen onAGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PB-SCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39% (95% confidence interval [CI], 37%-41%) in the SD cohort and 59% (95% CI, 57%-61%) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, or RIC + PB-SCs had lower risks of grades B-DAGVHD than those in other treatment categories. The 5-year probabilities of survival were 46% (95% CI, 44%-49%) with SD transplants and 33% (95% CI, 31%-35%) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.

Original languageEnglish (US)
Pages (from-to)296-307
Number of pages12
JournalBlood
Volume119
Issue number1
DOIs
StatePublished - Jan 5 2012

Fingerprint

Transplants
Cell Transplantation
Survival
Irradiation
Whole-Body Irradiation
Confidence Intervals
Conditioning (Psychology)
Grafts
Blood
Unrelated Donors
Therapeutics
Siblings

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Jagasia, M., Arora, M., Flowers, M. E. D., Chao, N. J., McCarthy, P. L., Cutler, C. S., ... Hahn, T. (2012). Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood, 119(1), 296-307. https://doi.org/10.1182/blood-2011-06-364265

Risk factors for acute GVHD and survival after hematopoietic cell transplantation. / Jagasia, Madan; Arora, Mukta; Flowers, Mary E D; Chao, Nelson J.; McCarthy, Philip L.; Cutler, Corey S.; Urbano-Ispizua, Alvaro; Pavletic, Steven Z.; Haagenson, Michael D.; Zhang, Mei Jie; Antin, Joseph H.; Bolwell, Brian J.; Bredeson, Christopher; Cahn, Jean Yves; Cairo, Mitchell; Gale, Robert Peter; Gupta, Vikas; Lee, Stephanie J.; Litzow, Mark R; Weisdorf, Daniel J.; Horowitz, Mary M.; Hahn, Theresa.

In: Blood, Vol. 119, No. 1, 05.01.2012, p. 296-307.

Research output: Contribution to journalArticle

Jagasia, M, Arora, M, Flowers, MED, Chao, NJ, McCarthy, PL, Cutler, CS, Urbano-Ispizua, A, Pavletic, SZ, Haagenson, MD, Zhang, MJ, Antin, JH, Bolwell, BJ, Bredeson, C, Cahn, JY, Cairo, M, Gale, RP, Gupta, V, Lee, SJ, Litzow, MR, Weisdorf, DJ, Horowitz, MM & Hahn, T 2012, 'Risk factors for acute GVHD and survival after hematopoietic cell transplantation', Blood, vol. 119, no. 1, pp. 296-307. https://doi.org/10.1182/blood-2011-06-364265
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012 Jan 5;119(1):296-307. https://doi.org/10.1182/blood-2011-06-364265
Jagasia, Madan ; Arora, Mukta ; Flowers, Mary E D ; Chao, Nelson J. ; McCarthy, Philip L. ; Cutler, Corey S. ; Urbano-Ispizua, Alvaro ; Pavletic, Steven Z. ; Haagenson, Michael D. ; Zhang, Mei Jie ; Antin, Joseph H. ; Bolwell, Brian J. ; Bredeson, Christopher ; Cahn, Jean Yves ; Cairo, Mitchell ; Gale, Robert Peter ; Gupta, Vikas ; Lee, Stephanie J. ; Litzow, Mark R ; Weisdorf, Daniel J. ; Horowitz, Mary M. ; Hahn, Theresa. / Risk factors for acute GVHD and survival after hematopoietic cell transplantation. In: Blood. 2012 ; Vol. 119, No. 1. pp. 296-307.
@article{822a0f36762640378462b0e84610f4dc,
title = "Risk factors for acute GVHD and survival after hematopoietic cell transplantation",
abstract = "Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen onAGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PB-SCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39{\%} (95{\%} confidence interval [CI], 37{\%}-41{\%}) in the SD cohort and 59{\%} (95{\%} CI, 57{\%}-61{\%}) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, or RIC + PB-SCs had lower risks of grades B-DAGVHD than those in other treatment categories. The 5-year probabilities of survival were 46{\%} (95{\%} CI, 44{\%}-49{\%}) with SD transplants and 33{\%} (95{\%} CI, 31{\%}-35{\%}) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.",
author = "Madan Jagasia and Mukta Arora and Flowers, {Mary E D} and Chao, {Nelson J.} and McCarthy, {Philip L.} and Cutler, {Corey S.} and Alvaro Urbano-Ispizua and Pavletic, {Steven Z.} and Haagenson, {Michael D.} and Zhang, {Mei Jie} and Antin, {Joseph H.} and Bolwell, {Brian J.} and Christopher Bredeson and Cahn, {Jean Yves} and Mitchell Cairo and Gale, {Robert Peter} and Vikas Gupta and Lee, {Stephanie J.} and Litzow, {Mark R} and Weisdorf, {Daniel J.} and Horowitz, {Mary M.} and Theresa Hahn",
year = "2012",
month = "1",
day = "5",
doi = "10.1182/blood-2011-06-364265",
language = "English (US)",
volume = "119",
pages = "296--307",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Risk factors for acute GVHD and survival after hematopoietic cell transplantation

AU - Jagasia, Madan

AU - Arora, Mukta

AU - Flowers, Mary E D

AU - Chao, Nelson J.

AU - McCarthy, Philip L.

AU - Cutler, Corey S.

AU - Urbano-Ispizua, Alvaro

AU - Pavletic, Steven Z.

AU - Haagenson, Michael D.

AU - Zhang, Mei Jie

AU - Antin, Joseph H.

AU - Bolwell, Brian J.

AU - Bredeson, Christopher

AU - Cahn, Jean Yves

AU - Cairo, Mitchell

AU - Gale, Robert Peter

AU - Gupta, Vikas

AU - Lee, Stephanie J.

AU - Litzow, Mark R

AU - Weisdorf, Daniel J.

AU - Horowitz, Mary M.

AU - Hahn, Theresa

PY - 2012/1/5

Y1 - 2012/1/5

N2 - Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen onAGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PB-SCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39% (95% confidence interval [CI], 37%-41%) in the SD cohort and 59% (95% CI, 57%-61%) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, or RIC + PB-SCs had lower risks of grades B-DAGVHD than those in other treatment categories. The 5-year probabilities of survival were 46% (95% CI, 44%-49%) with SD transplants and 33% (95% CI, 31%-35%) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.

AB - Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen onAGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PB-SCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39% (95% confidence interval [CI], 37%-41%) in the SD cohort and 59% (95% CI, 57%-61%) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, or RIC + PB-SCs had lower risks of grades B-DAGVHD than those in other treatment categories. The 5-year probabilities of survival were 46% (95% CI, 44%-49%) with SD transplants and 33% (95% CI, 31%-35%) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.

UR - http://www.scopus.com/inward/record.url?scp=84862908566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862908566&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-06-364265

DO - 10.1182/blood-2011-06-364265

M3 - Article

C2 - 22010102

AN - SCOPUS:84862908566

VL - 119

SP - 296

EP - 307

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -